Premier Alternatives

LeadingTac

Shanghai, China · Founded 2019 · Privately Held (backing)

Developer of small-molecule innovative therapeutics intended for the treatment of autoimmune and tumor diseases. LeadingTac is based in Shanghai, China and was founded in 2019. Its last reported valuation was $8.5 million in Nov 2019. It has raised $63.8 million.

Last reported valuation
$8.5M
Oct 2026
Priced at
—
Total raised
$63.8M
Last round
—

LeadingTac key facts

as of Oct 2026
  • Developer of small-molecule innovative therapeutics intended for the treatment of autoimmune and tumor diseases.
  • LeadingTac is valued at approximately $8.5M as of Oct 2026 (last reported valuation).
  • It has raised $63.8M; the latest was Early Stage VC ($31.1M) in Dec 2025.
  • Notable investors include CDH Investments, YuanBio Venture Capital, Lapam Capital, Hankang Capital, Zhangjiang Group — 8 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$8.5M

LeadingTac's last reported valuation, Nov 2019. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of LeadingTac with a free account
  • ·Watch LeadingTac: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

LeadingTac funding rounds

No rounds on record

No funding rounds for LeadingTac are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

LeadingTac valuation

LeadingTac's last reported valuation was $8.5 million in Nov 2019. No priced round, secondary trade or fund mark has surfaced since.

LeadingTac investors

8 investors are on record for LeadingTac, including CDH Investments, YuanBio Venture Capital, Lapam Capital and Hankang Capital.

About LeadingTac

Developer of small-molecule innovative therapeutics intended for the treatment of autoimmune and tumor diseases. The company offers research platforms and drug candidates leveraging targeted protein degradation technologies, proprietary intracellular and extracellular protein ubiquitination systems, modular small molecule compounds with E3 ligase recruitment, secure clinical trial progression infrastructure, and global intellectual property coverage, enabling biopharma developers, clinicians, and research collaborators to advance first in class therapeutic candidates through preclinical and clinical stages with enhanced target specificity and streamlined development pathways.

Sector
Healthcare
HQ
Shanghai, China
Founded
2019
Employees
30
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.